




		<b>EMLc</b>	ATC codes: <b>L01AA06</b>
<b>Indication</b>	Ewing sarcoma of bone and articular cartilage of unspecified sites	ICD11 code: <b>2C22.Z</b>	
<b>INN</b>	Ifosfamide		
<b>Medicine type</b>	Chemical agent		
<b>List type</b>	Complementary (EML) (EMLc)		
<b>Formulations</b>	Parenteral > General injections > IV: 500 mg in vial powder for injection ; 1 g in vial powder for injection ; 2 g in vial powder for injection		
<b>EML status history</b>	First added in 2009 ( <b>TRS 958</b> ) Changed in 2015 ( <b>TRS 994</b> )		
<b>Sex</b>	All		
<b>Age</b>	Also recommended for children		
<b>Therapeutic alternatives</b>	The recommendation is for this specific medicine		
<b>Patent information</b>	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 		
<b>Tags</b>	<span>Cancer</span>		
<b>Wikipedia</b>	<a href="#">Ifosfamide</a> 		
<b>DrugBank</b>	<a href="#">Ifosfamide</a> 		

## Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for ifosfamide on the complementary list of the EML for use in treatment protocols for Ewing sarcoma was specifically endorsed. Additionally, ifosfamide was added on the complementary list of the EMLc for this indication. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for Ewing sarcoma is attached.

Expert Committee report 
